Earnings Call Summary | Baxter International Inc(BAX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Baxter International Inc(BAX.US) Q1 2024 Earnings Conference
The following is a summary of the Baxter International Inc. (BAX) Q1 2024 Earnings Call Transcript:
以下是百特國際公司（BAX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Baxter International reported Q1 sales from continuing operations of $3.6 billion, reflecting an increase of 2% on a reported basis and 33% from the prior year.
Adjusted earnings per share for continuing operations of $0.65 exceeded prior guidance range of $0.59 to $0.62 per share.
They anticipate sales growth in pharmaceuticals from 6% to 7%.
Full year adjusted earnings are projected to be around $2.88 to $2.98 per diluted share.
Estimates include sales growth across the businesses by 3% to 4% in 2024.
The company still plans to increase its adjusted operating margin by at least 50 basis points in 2024.
Baxter sees an annual tax rate between 22.0% to 22.5%.
百特國際報告稱，第一季度持續經營業務的銷售額爲36億美元，按報告計算增長了2％，比上年增長了33％。
調整後的持續經營業務每股收益爲0.65美元，超過了先前指導的每股0.59美元至0.62美元的區間。
他們預計藥品的銷售額將從6％增長到7％。
全年調整後每股收益預計約爲2.88美元至2.98美元。
估計值包括2024年各業務的銷售增長3％至4％。
該公司仍計劃在2024年將其調整後的營業利潤率提高至少50個點子。
百特認爲，年稅率在22.0％至22.5％之間。
Business Progress:
業務進展：
The Pharma segment achieved 11% growth in Q1, driven by new product launches in the U.S.
Baxter's Kidney Care segment demonstrated 3% growth at reported rates and 4% at constant currency.
Baxter secured U.S. FDA clearance for the Novum IQ volume infusion pump and Dose IQ Safety Software, bolstering their portfolio of connected care solutions.
Plans are underway for the proposed separation of the Kidney Care business in the second half of 2024.
R&D investments are focused on tech advancements and establishing new R&D centers in Ireland and the East Coast of the U.S.
Baxter emphasizes on launching new products and expanding in the pharmaceutical segment, especially premix products with high gross margins.
The company plans to enhance its global reach by strengthening its teams across various markets including, Asia-Pacific, Western Europe, and Latin America.
Baxter is expecting double-digit growth from their Spectrum pump and has a strong product pipeline including the newly launched Novum.
Baxter International is focused on improving operational efficiencies, evidenced by the creation of a new global business services leader role.
在美國新產品發佈的推動下，製藥板塊在第一季度實現了11％的增長。
百特的腎臟護理板塊按報告的增長率計算增長了3％，按固定匯率計算增長了4％。
百特獲得了美國食品藥品管理局對Novum IQ容量輸液泵和Dose IQ安全軟件的許可，從而增強了他們的互聯醫療解決方案組合。
計劃在2024年下半年分離腎臟護理業務。
研發投資側重於技術進步以及在愛爾蘭和美國東海岸建立新的研發中心。
百特強調推出新產品和擴大製藥領域的業務，尤其是毛利率高的預混產品。
該公司計劃通過加強包括亞太、西歐和拉丁美洲在內的各個市場的團隊來擴大其全球影響力。
百特預計其Spectrum泵將實現兩位數的增長，並擁有強大的產品線，包括新推出的Novum。
百特國際專注於提高運營效率，設立新的全球商業服務領導者職位就證明了這一點。
More details: Baxter International Inc IR
更多詳情： 百特國際公司投資者關係
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。